Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 19/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31192594 | 1.00 | CALCRL (0.55) | CALCRL | |
| SCHEMBL29151374 | 0.96 | HCAR1 (0.53) | CALCRL | |
| SCHEMBL30721751 | 0.94 | CALCRL (0.51) | CALCRL | |
| SCHEMBL29151432 | 0.94 | CALCRL (0.51) | CALCRL | |
| SCHEMBL3063134 | 0.86 | CHRM2 (0.64) | CALCRL | |
| SCHEMBL6580100 | 0.85 | CHRM2 (0.58) | CALCRL | |
| SCHEMBL12087688 | 0.84 | CALCRL (0.61) | CALCRL | |
| SCHEMBL2248725 | 0.84 | CCR5 (0.52) | CALCRL | |
| SCHEMBL2100682 | 0.83 | CALCRL (0.63) | CALCRL | |
| SCHEMBL2989677 | 0.82 | CHRM1 (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240208966-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-2-ONE AND/OR DERIVATIVES THEREOF | SIEGFRIED AG (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240208966-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-2-ONE AND/OR DERIVATIVES THEREOF | SIEGFRIED AG (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240208966-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-2-ONE AND/OR DERIVATIVES THEREOF | SIEGFRIED AG (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4323357-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-2-ONE AND/OR DERIVATIVES THEREOF | Siegfried AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-117460733-A | Synthesis method of 1, 3-dihydroimidazo [4,5-b ] pyridin-2-one and/or derivative thereof | 斯福瑞股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| US-20230092890-A1 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2023-03-23 | — | — | US | disclosed |
| WO-2022218811-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-2-ONE AND/OR DERIVATIVES THEREOF | SIEGFRIED AG (CH) | 2022-10-20 | — | — | WO | disclosed |
| EP-4074712-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-2-ONE AND/OR DERIVATIVES THEREOF | Siegfried AG (CH) | 2022-10-19 | — | — | EP | disclosed |
| US-20070111204-A1 | Methods for detecting nucleic acid variations | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | 2007-05-17 | — | — | US | disclosed |
| US-20060135511-A1 | Benzodiazepine cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-06-22 | — | — | US | disclosed |
| WO-2006044449-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044504-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1638969-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050256098-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2005-11-17 | — | — | US | disclosed |
| US-6953790-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040229861-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2004-11-18 | — | — | US | disclosed |
| WO-2004092166-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092168-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135511-A1 | Benzodiazepine cgrp receptor antagonists | NPY1R, NPY2R, CCKBR | CALCRL 12/4885 |
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | CALCRL 3149/4885 |
| US-20230092890-A1 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC6, HDAC1, HDAC2 | CALCRL 4859/4885 |
| US-20040229861-A1 | CGRP receptor antagonists | CCKBR, CCKAR, CALCRL | CALCRL 3/4885 |
| US-20070111204-A1 | Methods for detecting nucleic acid variations | POLN, LIG4, NCL | CALCRL 1841/4885 |
| US-20050256098-A1 | CGRP receptor antagonists | CCKBR, BDKRB1, BDKRB2 | CALCRL 6/4885 |
| US-20240208966-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-2-ONE AND/OR DERIVATIVES THEREOF | PDXK, CYP1B1, CYP2F1 | CALCRL 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.